tbuckley/cabot-search huggingface dataset:
The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer
Authors: Michael J. Raphael, Andrew Robinson, Christopher M. Booth, Jennifer O’Donnell, Michael Palmer, Elizabeth Eisenhauer, Michael Brundage
Journal: JAMA Oncology (2019)

<h3>Importance</h3> It is unclear whether patients with advanced cancer value surrogate end points, particularly progression-free survival (PFS). Despite this uncertainty, surrogate end points form the basis of regulatory approval for the majority of new cancer treatments. <h3>Objective</h3> To summarize and qualitatively assess studies evaluating whether patients with advanced cancer understand and value PFS. <h3>Evidence Review</h3> MEDLINE, Embase, the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials, and the Cumulative Index to Nursing and Allied Health Literature databases were searched from database inception to November 12, 2018. Articles eligible for inclusion investigated patient understanding, preference, or perceived value of disease progression or PFS in the setting of advanced cancer. Three authors independently reviewed and extracted data from all studies eligible for inclusion. <h3>Findings</h3> In total, 17 studies representing 3646 patients were included. Of these studies, 15 specifically aimed to assess patients' values toward, and their willingness to trade off toxic effects for gains or losses in the end point of PFS. All studies examined used widely disparate definitions when attempting to describe the meaning of PFS to patients. Ten studies specifically presented patients with the term<i>progression-free survival</i>as an attribute choice. In the words used to define the attribute of PFS, 6 studies used the term<i>survival</i>. Five studies clarified that PFS may not translate into better overall survival, and 5 studies explained that improvements in PFS may not reflect how well the patient may feel. No study clarified that a PFS event could represent either progression or death, and no study defined for the patient what constituted progression. The studies assessed herein underrepresented ethnic and racial minorities (mean percentage of white patients, 88%; range, 77%-96%). Values and preferences may vary across cultural backgrounds given that different relative preferences were assigned to cost and efficacy outcomes in North American vs Asian studies, although only a few studies were evaluated. <h3>Conclusions and Relevance</h3> The existing literature evaluating patients' understanding, preferences, and values toward the end point of PFS was severely limited by the heterogeneity of methods, attribute selection, and descriptions used to define PFS to patients. High-quality studies are needed that clearly define PFS for patients and that systematically document their understanding of the term. Only then can it be assessed whether PFS is an end point of value to patients with advanced cancer.
TCT-702 Impact of Transcatheter Aortic Valve Replacement on Anemia: New Approach to Heyde’s Syndrome
Authors: Javier Lopez-Pais, Diego Lopez Otero, Pablo Antunez Muinos, Barbara Izquierdo Coronel, Marta Perez Poza, Xabier Cia Mendioroz, Leyre Álvarez Rodríguez, Arturo Garcia-Touchard, Ana Belen Cid Alvarez, Ramiro Trillo Nouche, Juan Francisco Oteo Dominguez
Journal: Journal of the American College of Cardiology (2019)
TCT-575 Outcomes With Deferred Compared With Performed Revascularization of Coronary Lesions With Fractional Flow Reserve Values in the “Grey-Zone”
Authors: Michael Megaly, Charl Khalil, Marwan Saad, Iosif Xenogiannis, Mohamed Omer, Mahesh Anantha Narayanan, Ashish Pershad, Santiago Garcia, Arnold Seto, M. Nicholas Burke, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2019)
Numerous Pink-Purple Papules in a Middle-aged Man
Authors: Michael R. Stephens, Paul L. Haun, Robert G. Micheletti
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Lin28b controls a neonatal to adult switch in B cell positive selection
Authors: Stijn Vanhee, Hugo Åkerstrand, Trine Ahn Kristiansen, Sebak Datta, Giorgia Montano, Stefano Vergani, Stefan Lang, Jonas Ungerbäck, Alexander Doyle, Karin Olsson, Giulia Beneventi, Christina T. Jensen, Cristian Bellodi, Shamit Soneji, Mikael Sigvardsson, Elin Jaensson Gyllenbäck, Joan Yuan
Journal: Science Immunology (2019)

Temporally restricted expression of Lin28b promotes generation of self-reactive B-1 cells early in life.
TCT-405 The Fading Role of Triple Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome: A Bayesian Network Meta-Analysis
Authors: Mohammed Osman, Babikir Kheiri, Jason Moreland, Muhamad Munir, Sudarshan Balla, Samir Kapadia
Journal: Journal of the American College of Cardiology (2019)
TCT-841 The Impact of HIV on Coronary Artery Procedure in Patients of Coronary Artery Disease
Authors: Amer N. Kadri, Hassan Alkhawam, Ismail Hader, Johnny Chahine, Mohamed Gad, Rama Dilip Gajulapalli, Ahmed Ali, Adrian V. Hernandez, Steven Werns, Samir Kapadia
Journal: Journal of the American College of Cardiology (2019)
Predictive factors of grade 3-5 toxicity in older patients with cancer treated with chemotherapy: A prospective multicenter study.
Authors: Jaime Feliu Batlle, Laura Basterretxea, Maria Dolores Torregrosa, Elisenda Llabres, Beatriz Losada Vila, Beatriz Jimenez-Munarriz, Maite Antonio Rebollo, Ana B. Custodio, Regina Girones, Patricia Cruz, Mar Munoz Sanchez, Alvaro Pinto, Gemma Soler, Teresa Soria Comes, Hellis Telleria, MJ Molina-Garrido
Journal: Journal of Clinical Oncology (2019)

11509 Background: Older patients have increased risk of toxicity from chemotherapy. The purpose of this study was to analyse predictive factors for developing grade 3-5 toxicity in older patients treated with chemotherapy. Methods: This prospective multicenter study included 500 cancer patients ≥ 70 years between Feb 2014 and Jun 2018. A prechemotherapy assessment including sociodemographics, tumor/treatment variables, laboratory test results, and geriatric assessment variables (function, comorbidity, cognition, psychological state, social activity/support, and nutritional status) was performed. Logistic regression was used to examine the association between these factors and the development of grade 3-5 toxicity. Results: Mean age of the patients was 77 years (70-92), ECOG PS 0/1/2: 25%/63%/12%. 223 (45%) had a primary dose reduction.167 (33%) patients developed grade 3-5 toxicity (28% grade 3, 5% grade 4, 1% grade 5). Univariate analysis found a higher risk of grade 3-5 toxicity in patients with creatinine clearance ≤ 60 mL/min, IADL ≤7, VES13 ≥ 6, and the administration of standard chemotherapy doses. In multivariable analysis, only the chemotherapy dose (odds ratio [OR] 1.179; 95% confidence interval [CI] 1.215–2.655) and creatinine clearance (odds ratio [OR] 0.989; 95% confidence interval [CI] 0.981–0.997) were independently associated with toxicity. Conclusions: Renal function and chemotherapy dose were significant predictors of grade 3-5 toxicity among older patients treated with chemotherapy.
TCT-674 In-Stent Restenosis in Saphenous Vein Grafts: Insights From the DIVA trial
Authors: Iosif Xenogiannis, Bavana Rangan, Lauren Uyeda, Subhash Banerjee, Robert Edson, Deepak Bhatt, David Holmes, Sunil Rao, Kreton Mavromatis, Kodangudi Ramanathan, Edward McFalls, Santiago Garcia, Barry Uretsky, Faisal Latif, Ehrin Armstrong, Jose Ortiz, Hani Jneid, Jayson Liu, Kul Aggarwal, Todd Conner, Todd Wagner, Judit Karacsonyi, Beverly Ventura, Ying Lu, Mei-Chiung Shih, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2019)
Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies
Authors: April Armstrong, David Amato, William Huster, Clement Ojeh, Abby S. Van Voorhees
Journal: Journal of the American Academy of Dermatology (2019)

BackgroundThe National Psoriasis Foundation (NPF) published treatment targets for US patients with plaque psoriasis. However, data are lacking on how well existing therapies help achieve these goals.ObjectiveTo examine the ability of an interleukin 17 inhibitor, ixekizumab, in achieving these treatment targets.MethodsPost hoc analysis was performed on pooled data from 4 phase III clinical trials assessing ixekizumab for plaque psoriasis: the UNCOVER-1, -2, and -3 trials and the IXORA-S trial. Treatment response was evaluated using the NPF-defined acceptable response (affected body surface area [BSA] of 3% or less or BSA improvement of 75% or higher at 12 weeks of treatment) and target response (BSA of 1% or less at 12 weeks and every 6 months thereafter).ResultsIn the UNCOVER trials (n = 2701), acceptable and target response rates at week 12 were 73.9% and 51.8% with ixekizumab 80 mg every 2 weeks, 35.7% and 14.9% with etanercept 50 mg, and 3.0% and 0.6% with placebo, respectively. In the IXORA-S trial (n = 302), acceptable and target response rates at week 12 were significantly higher with ixekizumab every 2 weeks versus ustekinumab (acceptable response 68.4% vs 38.6%, P < .0001; target response 50.7% vs 24.1%, P < .0001).LimitationsData were from controlled studies and may not reflect real-world practice.ConclusionThe majority of patients treated with ixekizumab in 4 phase III clinical trials achieved NPF, patient-centered treatment targets. The National Psoriasis Foundation (NPF) published treatment targets for US patients with plaque psoriasis. However, data are lacking on how well existing therapies help achieve these goals. To examine the ability of an interleukin 17 inhibitor, ixekizumab, in achieving these treatment targets. Post hoc analysis was performed on pooled data from 4 phase III clinical trials assessing ixekizumab for plaque psoriasis: the UNCOVER-1, -2, and -3 trials and the IXORA-S trial. Treatment response was evaluated using the NPF-defined acceptable response (affected body surface area [BSA] of 3% or less or BSA improvement of 75% or higher at 12 weeks of treatment) and target response (BSA of 1% or less at 12 weeks and every 6 months thereafter). In the UNCOVER trials (n = 2701), acceptable and target response rates at week 12 were 73.9% and 51.8% with ixekizumab 80 mg every 2 weeks, 35.7% and 14.9% with etanercept 50 mg, and 3.0% and 0.6% with placebo, respectively. In the IXORA-S trial (n = 302), acceptable and target response rates at week 12 were significantly higher with ixekizumab every 2 weeks versus ustekinumab (acceptable response 68.4% vs 38.6%, P < .0001; target response 50.7% vs 24.1%, P < .0001). Data were from controlled studies and may not reflect real-world practice. The majority of patients treated with ixekizumab in 4 phase III clinical trials achieved NPF, patient-centered treatment targets.
TCT-636 Impact of Diabetes on the Outcomes in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Analysis From the GLOBAL LEADERS Study
Authors: Ply Chichareon, Rodrigo Modolo, Norihiro Kogame, Kuniaki Takahashi, Chun-Chin Chang, Mariusz Tomaniak, Christopher Raffel, Roberto Botelho, Eric Eeckhout, Sjoerd H. Hofma, Diana Trendafilova, Zsolt Koszegi, Andres Iñiguez, Joanna Wykrzykowska, Jan Piek, Scot Garg, Christian Hamm, Peter Juni, Marco Valgimigli, Stephan Windecker, Yoshinobu Onuma, Patrick Serruys
Journal: Journal of the American College of Cardiology (2019)
TCT-759 Invasive Versus Echocardiographic Evaluation of Suboptimal Valve Hemodynamics and Procedural Futility Following Valve-in-Valve Transcatheter Aortic Valve Replacement
Authors: Amr Abbas, Ramy Mando, George Hanzel, Michael Gallagher, Robert Safian, Safwan Kassas, Francis Shannon
Journal: Journal of the American College of Cardiology (2019)
3D printing of silk fibroin-based hybrid scaffold treated with platelet rich plasma for bone tissue engineering
Authors: Liang Wei, Shaohua Wu, Mitchell Kuss, Xiping Jiang, Runjun Sun, Patrick Reid, Xiaohong Qin, Bin Duan
Journal: Bioactive Materials (2019)

3D printing/bioprinting are promising techniques to fabricate scaffolds with well controlled and patient-specific structures and architectures for bone tissue engineering. In this study, we developed a composite bioink consisting of silk fibroin (SF), gelatin (GEL), hyaluronic acid (HA), and tricalcium phosphate (TCP) and 3D bioprinted the silk fibroin-based hybrid scaffolds. The 3D bioprinted scaffolds with dual crosslinking were further treated with human platelet-rich plasma (PRP) to generate PRP coated scaffolds. Live/Dead and MTT assays demonstrated that PRP treatment could obviously promote the cell growth and proliferation of human adipose derived mesenchymal stem cells (HADMSC). In addition, the treatment of PRP did not significantly affect alkaline phosphatase (ALP) activity and expression, but significantly upregulated the gene expression levels of late osteogenic markers. This study demonstrated that the 3D printing of silk fibroin-based hybrid scaffolds, in combination with PRP post-treatment, might be a more efficient strategy to promote osteogenic differentiation of adult stem cells and has significant potential to be used for bone tissue engineering.
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
Authors: Luca Richeldi, Evans R Fernández Pérez, Ulrich Costabel, Carlo Albera, David J Lederer, Kevin R Flaherty, Neil Ettinger, Rafael Perez, Mary Beth Scholand, Jonathan Goldin, Kin-Hung Peony Yu, Thomas Neff, Seth Porter, Ming Zhong, Eduard Gorina, Elias Kouchakji, Ganesh Raghu
Journal: The Lancet Respiratory Medicine (2019)
Multiple Transients of Local Gas Redistribution During Spontaneous Breathing Are Influenced by Ventilatory Settings
Authors: Gaetano Perchiazzi, Mariangela Pellegrini, Göran Hedenstierna, Agneta Roneus, Anders S. Larsson
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Multiple Transients of Local Gas Redistribution During Spontaneous Breathing Are Influenced by Ventilatory Settings
TCT-663 Very Very Late Stent Thrombosis Beyond 5 Years: Some Wounds Never Heal
Authors: Alejandro Gutierrez-Barrios, Livia L. Gheorghe, Diego Mialdea, Dolores Cañadas, Inmaculada Noval-Morillas, Santiago Camacho Freire
Journal: Journal of the American College of Cardiology (2019)
TCT-596 Reducing Left Ventricular Sphericity With a Trans-Ventricular Myocardial Splint Improves Systolic Function in a Preclinical Ischemic Cardiomyopathy Model
Authors: Daisuke Onohara, Daniella Espiritu, Takanori Kono, Roberto Hernandez-Merlo, Robert Guyton
Journal: Journal of the American College of Cardiology (2019)
INNOMINATE ANEURYSM: SIMULTANEOUS LIGATURE OF RIGHT CAROTID AND SUBCLAVIAN ARTERIES: RECOVERY
Authors: H. N. Dunn
Journal: BMJ (1905)

CAROTID AND SiJBOBLAIAf FOR INNOMINATE ANEURYSM. [°8Sr up of the iliac and lumbar fasciae.The ureter was raised with the peritonenm.An excellent view of the external and common iliac arteries was obtained, and the bleeding
Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 (HSV-1) for peritoneal carcinomatosis in mice
Authors: Yakup Kulu, Darshini Kuruppu, Bryan Fuchs, Jonathan Goodwin, Jon Dorfman, Tsutomu Fujii, Michael Lanuti, Kenneth Tanabe
Journal: Cancer Research (2007)

3302  Gastrointestinal malignancies frequently recur with metastatic disease limited to the abdominal cavity. Current treatments for peritoneal carcinomatosis are of limited efficacy, and median survival time after diagnosis is less than 9 months. We previously demonstrated that a single intravascular administration of an oncolytic HSV-1 mutant (hrR3) into immune-competent mice bearing diffuse colorectal carcinoma liver metastases significantly reduces tumor burden and prolongs animal survival. In the current study we compared survival benefit and biodistribution of hrR3 following intravenous (IV) versus intraperitoneal (IP) administration of hrR3 in immune-competent mice bearing peritoneal colon carcinoma metastases.  Methods: hrR3 is engineered such that it replicates preferentially in tumor cells because of its defective expression of viral ribonucleotide reductase. Animals bearing peritoneal metastases were randomized to receive hrR3 by either IP or IV administration. Mice were treated with 1x10E8 pfu hrR3 every other day for a total of 3 doses. Control animals received IP mock-infected media. Biodistribution was assessed by polymerase chain reaction amplification of HSV-1 specific sequences from tissue samples including tumor and normal gut, liver, spleen, kidney, lung, heart and brain. Animals were monitored for survival to determine efficacy of treatment.  Results: The frequency of detection of hrR3 in tumors was similar in mice randomized to either IP or IV administration. However, IP administration resulted in a more restricted biodistribution, with a reduction in frequency of hrR3 detection in normal tissues such as kidney, lung, and heart. The frequency of distribution to normal liver was similar in IP and IV groups. Observed survival was similar amongst the groups, with a median survival of 13 days after the final hrR3 dose.  Conclusions: Frequency of hrR3 detection in peritoneal tumors is similar following IV or IP administration, and overall survival of the animals is similar. However, the IP group is observed to have a more restricted (favorable) biodistribution of virus to normal tissues. Thus, subsequent studies evaluating the relationship between dose-schedule and toxicity will be evaluated using the IP route of administration.
Catheterization of the Urethra in Girls
Authors: Sergio Manzano, Aaron Vunda, Franck Schneider, Lynda Vandertuin, Laurence E. Lacroix
Journal: New England Journal of Medicine (2014)

Urethral catheterization permits direct drainage of the urinary bladder and is often performed in pediatric practice. This video demonstrates catheterization of the urinary bladder in the female infant or child.
Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
Authors: Ziyu Li, Fei Shan, Xiangji Ying, Yan Zhang, Jian-Yu E, Yinkui Wang, Hui Ren, Xiangqian Su, Jiafu Ji
Journal: JAMA Surgery (2019)

Laparoscopic distal gastrectomy and neoadjuvant chemotherapy are increasingly used to treat locally advanced gastric cancer. However, the safety and efficacy of the laparoscopic procedure after neoadjuvant chemotherapy remain unclear.
Hay Fever and Its Successful Treatment.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PTH-087 First analysis from uk ibd twin biobank; 16s rrna gene sequencing identifies reduced diversity in active ibd and taxa associated with active disease phenotype to level of species
Authors: J McDonald, H Gordon, W Blad, T Orchard, J Marchesi
Journal: Gut (2017)

Introduction  Previous studies have shown that the gut microbiota plays an important role in IBD, however there is not a consensus on which bacteria are responsible for the disease. 16S gene profiling studies generate large amounts of information, however they can be confounded by genetic and environmental factors. Twin studies are instrumental in controlling for some of these variabilities, and in this study we investigated the microbiota of twin pairs discordant for Crohn’s disease (CD) and ulcerative colitis (UC) using 16S rRNA gene sequencing, with the aim of identifying taxa associated with disease.  Method  Participants were recruited via the UK IBD Twin Registry. Stool samples were collected and frozen using standard methods. Participants who had received antibiotics within 3 months were excluded. Harvey Bradshaw Index and Simple Clinical Colitis Activity Index were recorded. Full medical history was available from the UK IBD Twin Registry.  Samples underwent 16S rRNA sequencing using the Illumina MiSeq platform and analysed using our data analysis pipeline. PERMANOVA was used to evaluate associations with clinical metadata, which included matching of twin pairs for analysis, and STAMP was used to identify taxonomic differences between groups.  Results  20 twin pairs discordant for CD (5MZ:15DZ mean age 52 years) and 17 discordant for UC (6MZ:11DZ mean age 59.7 years) were recruited. 7 subjects with CD had active disease as did 4 with UC.  Gut microbiota from active CD patients had lower bacterial diversity compared to remission CD patients and healthy twins (Shannon diversity index, p  We found that active CD patients had a higher proportion of Clostridium hylemonae and Lactobacillus delbrueckii compared to healthy twins, and a lower proportion of Bacteroides uniformis, Bacteroides vulgatus, and Faecalibacterium prausnitzii (p  Conclusion  This study confirms previous findings showing decreased diversity in IBD patients and changes in some bacterial taxa, however our study is the first to show decreases in Alistipes spp. in active UC.  Disclosure of Interest  None Declared
Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer
Authors: Ravi B. Parikh, Blythe J. S. Adamson, Sean Khozin, Matthew D. Galsky, Shrujal S. Baxi, Aaron Cohen, Ronac Mamtani
Journal: JAMA (2019)

This research letter discusses the association between label restrictions by the US Food and Drug Administration on first-line immunotherapy for advanced bladder cancer and subsequent changes in practice.